Loading...
ROCO
6499
Market cap193mUSD
Jul 09, Last price  
71.00TWD
1D
0.42%
1Q
-18.48%
Jan 2017
-25.03%
IPO
-36.84%
Name

Medeon Biodesign Inc

Chart & Performance

D1W1MN
ROCO:6499 chart
P/E
P/S
14.83
EPS
Div Yield, %
Shrs. gr., 5y
0.14%
Rev. gr., 5y
27.79%
Revenues
419m
+43.24%
453,763,000123,056,00068,957,000298,317,000196,263,000292,808,000419,425,000
Net income
-668m
L-17.06%
-261,985,000-192,735,0002,078,192,000-433,758,000-1,204,615,000-805,512,000-668,062,000
CFO
-629m
L-24.45%
-241,989,000-151,273,000-293,377,000-461,340,000-755,075,000-832,665,000-629,085,000
Dividend
Aug 23, 20230.49993 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular graft system; PUMA, solution to treat orthopedic extremity injuries; ClickClean, a solution to view throughout laparoscopic surgeries; and AbClose to prevent port site herniation caused by improper closure. It is engaged in the medical device contract manufacturing; and manufacture and sale of injection molding and components of medical devices. Medeon Biodesign, Inc. was incorporated in 2012 and is based in Taipei, Taiwan.
IPO date
Dec 11, 2014
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT